Skip to main content

Table 2 Structural lesion change according to sex in patients with axial spondyloarthritis, baseline to week 104

From: Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR

Structural lesion

Study cohort

Sex

Lesion decreased n/N (%)

Lesion increased n/N (%)

Net % patients with decrease within study cohort (95% CI)

P value for lesion decrease vs increase

P value for difference in sex (both studies pooled)

P value for difference in study (both sexes pooled)

P value for difference in sex (by study)

P value for difference in study (by sex)

 Erosion

Etanercept

(EMBARK)

Male

39/105 (37.1)

6/105 (5.7)

31.4% (21.3, 41.6)

< 0.001

0.048

0.03

0.02

0.02

 

Female

7/58 (12.1)

1/58 (1.7)

10.3% (− 3.3, 24.0)

0.14

   

0.38

Control

(DESIR)

Male

10/45 (22.2)

6/45 (13.3)

8.9% (− 6.6, 24.4)

0.26

  

0.47

 
 

Female

4/31 (12.9)

4/31 (12.9)

0% (− 18.7, 18.7)

1.0

    

Structural lesion

Study cohort

 

Lesion increased n/N (%)

Lesion decreased n/N (%)

Net % patients with increase within study cohort (95% CI)

P value for lesion increase vs decrease

P value for difference in sex (both studies pooled)

P value for difference in study (both sexes pooled)

P value for difference in sex (by study)

P value for difference in study (by sex)

 Backfill

Etanercept

(EMBARK)

Male

24/105 (22.9)

1/105 (1.0)

21.9% (14.6, 29.2)

< 0.001

0.03

0.50

0.008

0.21

 

Female

3/58 (5.2)

0/58 (0)

5.2% (− 4.6, 15.0)

0.30

   

0.88

Control

(DESIR)

Male

8/45 (17.8)

2/45 (4.4)

13.3% (2.2, 24.5)

0.02

  

0.44

 
 

Female

2/31 (6.5)

0/31 (0)

6.5% (− 7.0, 19.9)

0.35

    

 Fat metaplasia

Etanercept

(EMBARK)

Male

13/105 (12.4)

2/105 (1.9)

10.5% (4.7, 16.2)

< 0.001

0.03

0.61

0.07

0.59

 

Female

1/58 (1.7)

0/58 (0)

1.7% (− 6.0, 9.5)

0.66

   

0.82

Control

(DESIR)

Male

6/45 (13.3)

0/45 (0)

13.3% (4.6, 22.1)

0.003

  

0.15

 
 

Female

1/31 (3.2)

0/31 (0)

3.2% (− 7.4, 13.8)

0.55

    

 Ankylosis

Etanercept

(EMBARK)

Male

2/105 (1.9)

1/105 (1.0)

1.0% (− 1.8, 3.7)

0.50

0.24

0.47

0.26

0.62

 

Female

0/58 (0)

1/58 (1.7)

− 1.7% (− 5.5, 2.0)

0.37

   

0.59

Control

(DESIR)

Male

1/45 (2.2)

0/45 (0)

2.2% (− 2.0, 6.5)

0.31

  

0.51

 
 

Female

0/31 (0)

0/31 (0)

0% (− 5.1, 5.1)

1.0

    
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us